Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.39 |
| ▸ | HPGD | P15428 | 9/20 | 0.39 |
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 6/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200119 | 0.94 | KDM4E (0.38) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL339858 | 0.94 | KDM4E (0.39) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL18294654 | 0.92 | KDM4E (0.40) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL13232475 | 0.90 | ALDH1A1 (0.49) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL15233229 | 0.90 | KDM4E (0.37) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL10200459 | 0.86 | HPGD (0.35) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL13232467 | 0.81 | MAPT (0.40) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL13232463 | 0.79 | NPC1 (0.36) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL10200098 | 0.79 | ALDH1A1 (0.37) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL340641 | 0.77 | EDNRA (0.35) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | claimed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | claimed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | claimed |
| US-9717721-B2 | Use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry | TAIRX, INC. (TW) | 2017-08-01 | — | — | US | disclosed |
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| US-20160354361-A1 | NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY | TAIRX INC. (TW) | 2016-12-08 | — | — | US | disclosed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| EP-2593435-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009519-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | EFFICIENT PHARMA MANAGEMENT CORP. (TW) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354361-A1 | NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY | TEK, FLT1, VHL | KDM4E 1014/4885ALDH1A1 1091/4885HPGD 303/4885 |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | KDM4E 4748/4885ALDH1A1 1258/4885HPGD 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.